Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 6;11:4005–4021. doi: 10.2147/CMAR.S194607

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The potential predictors of patients’ responses to progestin therapy and recurrence Figure 3, including age, BMI, PCOS, type of hormonal agent used, and histology type (CAH or EC), were pooled for a meta-analysis. No substantial heterogeneity was found in any analysis of the patients’ response to progestin therapy. The I² values in each analysis were all less than 50% (6%, 18%, 0%, 0%, and 31%). There was no substantial heterogeneity in any analysis of recurrence. The I² values in all analyses were equal to zero.Abbreviation: PCOS, polycystic ovarian syndrome.